TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Major adverse cardiovascular events within 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tolerance to COX-2 inhibitors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum concentrations of estradiol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: uphill run performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: marksmanship ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in PMR-AS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain score (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FASD knowledge accuracy rate
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: TsB(0-24) (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to MMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Period of negative urine screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke volume at peak stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: goals of care documentation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: health care use and costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: cumulative probability of survival with respect to severe oral mucositis
Endpoint domain: Mortality/survival
Primary endpoint: intensity of oral pain
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: overall gastrointestinal symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Anxiety score (BAI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Performance on spatial declarative memory task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Performance on motor speed task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Global Quality of Life (GD)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: lower risk of respiratory-related hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of multiple organ dysfunction syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of systemic inflammatory response syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eliminating rate of conjunctival bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibiotic sensitivity of Gram-positive cocci to levofloxacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibiotic sensitivity of Gram-negative bacillus to levofloxacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: unsatisfactory post-LLETZ colposcopies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median distal motor latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: wakefulness after persistent sleep onset
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: latency to onset of persistent sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Platelet-monocyte aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: sCD40L concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: blood transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory restriction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Comfort level of immobilization methods
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: diastolic stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in engagement in transactional sex
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: serum adrenaline concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Sustained Virologic Response (SVR) at post-treatment week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean roughness and redness scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Subjective symptom parameters
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ocular surface findings by impression cytology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of HPV testing for detection of CIN2 or worse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative predictive value of HPV testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fetal NT thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5HIAA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: averted child deaths
Endpoint domain: Mortality/survival
Primary endpoint: Complete healing at 4 weeks after ESD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of defect area at 4 weeks after ESD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve (AUC₀‐∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum blood concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in child's behaviour
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction of fear for future treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in memory of experienced pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: days of healthcare outside home
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Oxygen saturations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ratings of withdrawal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reductions in craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of decline of graft function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of deep pockets resolved (PD reduction > or =3 mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GCF TGF‐beta1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sparteine metabolic ratio (MR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mephenytoin S/R ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability due to pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Relieving spasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: eKt/V improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occupational rehabilitation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: cumulative restoration success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent change in lumbar spine BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of uncorrected visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of photostress test recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular prognosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of hostile attributions in peer group entry scenarios
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Improvement in life quality after ending abusive relationship
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: percentage-of-doses-tracked
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Systolic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cortico-thalamic connectivity changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sum of Symptoms Intensity Difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Speed of action < 30 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total disappearance of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: lesion maintenance success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Investigator's Global Assessment score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Restoration of intestinal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of patients free of inappropriate therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High-energy shocks per patient per month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for ondansetron therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maternal body mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal eating style
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Player MVPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Player inactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of airway irritation events
Endpoint domain: Adverse events/effects
Primary endpoint: Mean expired desflurane concentration at first airway irritation symptom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contralateral putamen [123I]‐FP‐CIT uptake ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levodopa main outcome variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dyskinesia incidence
Endpoint domain: Adverse events/effects
Primary endpoint: investigator-rated response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: onset of clinical effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of clinical effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery phase duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: independence level
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: serum phosphate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: serum potassium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Quebec Back Pain Disability Scale score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects undergoing biopsy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Median time between screening and first follow-up chest CT
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: impulsiveness response style
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: discriminating ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: TAD (Tip-Apex Distance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of drilling attempts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percent reduction in flea counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of flea-free dogs on Day 90
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alleviation of clinical signs of flea allergy dermatitis (FAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pitch control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visceral adipose tissue reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cholesterol to HDL cholesterol ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postchallenge glucose concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postchallenge insulin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Detection of pathological intrapulmonary shunt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in oxygen indices after FiO2 modifications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Correlation of Qsp/Qt with PaO2/FiO2 and PaO2/PAO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: serum visfatin values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: YKL-40 levels in serum and sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AQLQ symptom domain improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AQLQ activity limitation domain improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 6MWD increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major malformations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Fear of childbirth (FOC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean score of the teacher professional development evaluation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average teacher implementation rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Student reception rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Extent of allodynia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Hamilton anxiety and depression scales
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Beck depression inventory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quit rates at 1, 3, 6 and 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Post-stimulation surgical pleth index values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diastolic flow velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: pulsatility index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: systolic/diastolic ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: resistance index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: arterial compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Improvement in lean body mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: in-segment LLL at 12-month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: TLF at 12-month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: serious or life-threatening visceral resuscitation-related damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of persistent diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: AUC of lapatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max) of lapatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life of lapatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating immune complex levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum copper levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 24 h urinary output of calcium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Two-minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EuroQol-5 Dimension
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: in-stent mean late lumen loss (LLL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Point prevalence abstinence at week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continuous abstinence at week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CEPCs number
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CEPCs proliferation capability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CEPCs adhesion function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of anatomically oriented diagnoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Response (CR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: AD intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication use frequency
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cortical State
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cortical Input
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients requiring antihypertensive medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of hypertensive episodes in the postanesthesia care unit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to discharge from postanesthesia care unit
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quality of oocytes and embryos
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implantation and pregnancy rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak NASS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean NASS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total blood loss during surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cumulative non-vellus hair width (TAHW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scalp coverage improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: change in fibromyalgia pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: eNO levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-DST cortisol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction in mean BSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically meaningful response (IGAxBSA-75)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful crossbite correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events related to tivantinib and/or erlotinib
Endpoint domain: Adverse events/effects
Primary endpoint: Long-term stable disease (≥24 weeks)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: CMMSE global score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: rate of pre-term birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Weight retention at 6 months postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PBMC telomerase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes